An Open-Label, Proof of Concept Study of Vorinostat for the Treatment of Moderate-to-Severe Crohn s Disease and Maintenance Therapy with Ustekinumab
A Natural History of the Collagen-Related Disorder Osteogenesis Imperfecta and the Genotype-Phenotype Correlation
The National Institutes of Health (NIH) is seeking children and adults with osteogenesis imperfect (OI) to join a study to learn more about the natural history of OI from childhood to adulthood and identify genes that play a role in the disease. This study is a part of the NIH Osteogenesis Imperfecta Translational Research Program, led by physician scientist, Joan Marini, M.D., Ph.D. The program has provided comprehensive care for children with OI for more than 30 years, while conducting clinical and laboratory research.
Low-Dose Danazol for the Treatment of Telomere Related Diseases
Researchers at the National Institutes of Health (NIH) are studying if the medication danazol can be used to treat people with short telomere disease who also have bone marrow failure, liver, or lung disease. In recent studies, danazol, at high doses, showed a positive influence on telomere length. Additional research is needed to learn more about the role of different doses of danazol on telomere disease as well as its effects on secondary diseases.
A Phase I Study of HERV-E TCR Transduced Autologous T Cells in Patients with Metastatic Clear Cell Renal Cell Carcinoma
Phase II Trial Evaluating Nivolumab in Patients with IDH-Mutant Gliomas with and without Hypermutator Phenotype
National Cancer Institute (NCI) researchers are conducting a study of patients with IDH-mutated gliomas. This study will test whether stimulating the immune system using the drug nivolumab can shrink recurrent IDH-mutant gliomas with and without hypermutator phenotype or increase the time it takes for them to grow or spread.